Arvinas, Inc. $ARVN Shares Sold by Nordea Investment Management AB

Nordea Investment Management AB decreased its stake in shares of Arvinas, Inc. (NASDAQ:ARVN) by 11.2% during the 4th quarter, Holdings Channel.com reports. The firm owned 495,477 shares of the company’s stock after selling 62,265 shares during the period. Nordea Investment Management AB’s holdings in Arvinas were worth $5,891,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of ARVN. Campbell & CO Investment Adviser LLC raised its holdings in Arvinas by 307.7% in the third quarter. Campbell & CO Investment Adviser LLC now owns 223,576 shares of the company’s stock valued at $1,905,000 after acquiring an additional 168,744 shares in the last quarter. SG Americas Securities LLC acquired a new position in Arvinas during the 2nd quarter worth approximately $390,000. 22NW LP acquired a new position in Arvinas during the 2nd quarter worth approximately $3,044,000. Velan Capital Investment Management LP purchased a new stake in shares of Arvinas in the 2nd quarter valued at approximately $3,680,000. Finally, BML Capital Management LLC purchased a new stake in shares of Arvinas in the 3rd quarter valued at approximately $426,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Trading Down 0.5%

Shares of Arvinas stock opened at $10.87 on Friday. The company has a fifty day simple moving average of $12.57 and a 200-day simple moving average of $11.23. The stock has a market cap of $695.26 million, a price-to-earnings ratio of -8.49 and a beta of 1.87. Arvinas, Inc. has a 12-month low of $5.90 and a 12-month high of $14.51.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The company had revenue of $9.50 million for the quarter, compared to analyst estimates of $37.26 million. During the same quarter in the prior year, the business earned ($0.63) earnings per share. Arvinas’s revenue was down 84.0% compared to the same quarter last year. On average, analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Insider Activity at Arvinas

In other news, Director John G. Houston sold 35,297 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $13.21, for a total value of $466,273.37. Following the completion of the sale, the director directly owned 1,122,183 shares of the company’s stock, valued at approximately $14,824,037.43. The trade was a 3.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Noah Berkowitz sold 6,435 shares of the company’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $11.10, for a total value of $71,428.50. Following the completion of the sale, the insider directly owned 202,503 shares of the company’s stock, valued at approximately $2,247,783.30. This trade represents a 3.08% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 63,864 shares of company stock valued at $802,443. Corporate insiders own 4.73% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on ARVN. BTIG Research lifted their price objective on shares of Arvinas from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Truist Financial set a $10.00 target price on Arvinas in a report on Wednesday, March 18th. Citigroup raised their price target on Arvinas from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arvinas in a report on Monday, December 22nd. Finally, Wedbush upped their price objective on Arvinas from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 24th. Ten investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Arvinas has a consensus rating of “Hold” and a consensus target price of $13.88.

Arvinas Company Profile

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.